We’re back with our 4th episode in our collaborative series with BMJ Thorax. This week’s episode covers four articles related to bronchiectasis and covers a range of topics in this domain including novel therapeutics, registry data to understand risk, and health related quality of life.
Our mission at Pulm PEEPs is to disseminate and promote pulmonary and critical care education, and we highly value the importance of peer reviewed journals in this endeavor. Each month in BMJ Thorax, a journal club is published looking at high yield and impactful publications in pulmonary medicine. We will be putting out quarterly episodes in association with Thorax to discuss a journal club publication and synthesize four valuable papers.
Meet Our Guests
Chris Turnbull is an Associate Editor for Education at Thorax. He is an Honorary Researcher and Respiratory Medicine Consultant at Oxford University Hospitals. In addition to his role as Associate Editor for Education at BMJ Thorax, he is also a prominent researcher in sleep-related breathing disorders.
Dr. George Doumat completed his medical school at the American University of Beirut and now is an internal medicine resident at UT south western in his second year of training. Prior to starting residency he was a research fellow at MGH studying chronic lung disease.
Journal Club Papers
*
Journal club paper from BMJ Thorax
*
Phase 3 Trial of the DPP-1 Inhibitor Brensocatib in Bronchiectasis
*
Cathepsin C (dipeptidyl peptidase 1) inhibition in adults with bronchiectasis: AIRLEAF, a phase II randomised, double-blind, placebo-controlled, dose-finding study
*
Five-Year Outcomes among U.S. Bronchiectasis and NTM Research Registry Patients
*
Anxiety, depression, physical disease parameters and health-related quality of life in the BronchUK national bronchiectasis cohort
To submit a journal club article of your own to Thorax, you can contact Chris directly – christopher.turnbull@ouh.nhs.uk
To engage with Thorax, please use the social media channels (Twitter –
@ThoraxBMJ; Facebook –
Thorax.BMJ) and subscribe on your preferred platform, to get the latest episodes directly on your device each month.
Key Learning Points
* Four recent papers (2 RCTs, 2 large cohorts) chosen to show both new therapeutics and real-world comorbidities/outcomes, pushing toward precision medicine.
1) ASPEN trial – brensocatib (DPP-1 inhibitor)
* Design: Phase 3, ~1,700 pts, 35 countries, 52 weeks; stratified randomization by region.
* Results: ↓ annualized exacerbation rate (~1.0 vs 1.3/yr; RR≈0.8), longer time to first exacerbation, ~10% absolute ↑ in “exacerbation-free” patients at 1 year, QoL improved, modest FEV1 decline difference (~40 mL/yr).
* Take: First targeted therapy with consistent benefit; effect on lung functi...
